Anti-inflammatory healing blend: TB-500 + BPC-157 + KPV + GHK-Cu
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 3.5 mg | Daily | Dose: 10 units (0.1 mL) Frequency: 5 days on / 2 off Per Injection: TB-10 → 0.5 mg BPC-157 → 0.5 mg KPV → 0.5 mg GHK-Cu → 2.5 mg |
| Intermediate | 5 mg | Daily | Dose: 20 units (0.2 mL) Frequency: Daily or 5 on / 2 off Per Injection: TB-10 → 1 mg BPC-157 → 1 mg KPV → 1 mg GHK-Cu → 5 mg |
| Advanced | 7 mg | Daily | Dose: 30–40 units (0.3–0.4 mL) Frequency: Daily for 2–4 weeks At 30 units (0.3 mL): TB-10 → 1.5 mg BPC-157 → 1.5 mg KPV → 1.5 mg GHK-Cu → 7.5 mg At 40 units (0.4 mL): TB-10 → 2 mg BPC-157 → 2 mg KPV → 2 mg GHK-Cu → 10 mg |
| Maximum | 10 mg | Daily | — |
Blend Dosing Approach
KLOW is formulated as a **fixed-ratio blend** with pre-determined concentrations of each peptide component, eliminating the need for users to calculate individual peptide dosing or manage multiple vials. This **pre-combined format** simplifies administration while ensuring optimal peptide ratios based on their complementary mechanisms of action. Since the peptides are already mixed in specific proportions, dosing becomes **volume-based** rather than concentration-based, with users measuring the desired volume of the complete blend. The peptides in this combination have compatible **pharmacokinetic profiles**, with most showing peak effects within 4-8 hours, making them suitable for concurrent administration. For optimal results, consistent timing and frequency should be maintained, as the **anti-inflammatory effects** of KPV and the **cellular migration** benefits of TB-500 work best with regular dosing intervals. The fixed-ratio approach also ensures that the **synergistic pathways** are consistently activated together, maximizing the potential for coordinated healing responses.
Per-Component Breakdown
Synergy Rationale
The KLOW blend strategically combines four peptides that address different stages and mechanisms of the **healing cascade** to create a comprehensive anti-inflammatory and regenerative response. **TB-500** provides the cellular mobility foundation by modulating actin dynamics, enabling cells to migrate efficiently to injury sites. **BPC-157** amplifies this effect by promoting **angiogenesis** and systemic tissue repair, ensuring adequate blood supply and nutrients reach healing tissues. **KPV** serves as the anti-inflammatory orchestrator, working through **melanocortin pathways** to reduce harmful cytokines while preserving beneficial healing signals. **GHK-Cu** completes the formulation by driving **collagen synthesis** and activating regenerative gene expression patterns essential for tissue remodeling. This combination targets the complete healing process: cellular migration, vascularization, inflammation control, and structural repair. The peptides share complementary pathways including **VEGF upregulation**, **anti-inflammatory signaling**, and **enhanced fibroblast activity**, creating multiple reinforcing mechanisms that support optimal healing environments while minimizing excessive inflammation that could impede recovery.
Combined Mechanism
The KLOW peptides create a synergistic network targeting multiple **healing pathways** simultaneously. **TB-500 and BPC-157** both upregulate **VEGF expression** and promote **angiogenesis**, with TB-500 facilitating endothelial cell migration through **actin regulation** while BPC-157 enhances **nitric oxide signaling** for improved blood flow. This vascular synergy ensures optimal nutrient delivery to healing tissues. **KPV** provides crucial **anti-inflammatory control** by inhibiting **NF-κB signaling** and reducing pro-inflammatory cytokines like **TNF-α and IL-6**, while simultaneously upregulating protective **IL-10** and **TGF-β**. This creates an ideal healing environment for the other peptides to function optimally. **GHK-Cu** amplifies the regenerative response by upregulating **collagen synthesis genes** and activating **TGF-β pathways** that complement KPV's anti-inflammatory TGF-β effects. The peptides also share **fibroblast activation** and **enhanced cell migration** mechanisms, with TB-500's actin modulation working synergistically with GHK-Cu's stem cell differentiation signals. Together, they create a **multi-pathway approach** that addresses inflammation reduction, cellular repair, vascular support, and structural regeneration simultaneously, potentially producing greater therapeutic effects than any single peptide alone.
Research Context
While extensive individual research exists for each peptide component, **direct studies on this specific four-peptide combination** are currently limited in peer-reviewed literature. However, research on similar **peptide combinations** suggests potential for **synergistic anti-inflammatory** and **healing effects**, particularly combinations involving TB-500 with BPC-157, which share overlapping **angiogenic pathways**. The rationale for combining these peptides is based on their **complementary mechanisms of action** rather than direct combination studies. Individual research demonstrates that **KPV and GHK-Cu** both modulate inflammatory responses through different but compatible pathways, while **TB-500 and BPC-157** enhance cellular repair through distinct but reinforcing mechanisms. Current understanding of **peptide synergy** in healing applications is evolving, with researchers increasingly investigating multi-peptide approaches for enhanced therapeutic outcomes. This represents an **active area of research interest**, though more specific studies on multi-peptide combinations are needed to fully characterize potential synergistic effects and optimal ratios for different therapeutic applications.
Research Use Only: All compounds discussed on this page are intended for laboratory research purposes only. Not for human consumption. All research should be conducted in compliance with institutional guidelines and applicable regulations. Consult qualified healthcare professionals before making any decisions regarding compound research or use.
KLOW
Quick Reference
- Default Dose
- 3.5 mg
- Frequency
- Daily
- Timing
- AM
- Dilution
- 2 mL
For Practitioners
Interested in offering research-grade compounds through your practice? Learn about our affiliate program for qualified practitioners.
Find a ProviderPractitioner Information